Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

AVAX TECHNOLOGIES INC (AVXT)

AVXT RSS Feed
Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 7/31/2014 1:27:31 PM - Followers: 18 - Board type: Free - Posts Today: 0

 

Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
Chairman and CEO: John K. A. Prendergast
CFO and Director: Richard P. (Rich) Rainey
 
 
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

 


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:

https://en.wikipedia.org/wiki/Avax_Technologies

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551891/

http://www.ncbi.nlm.nih.gov/pubmed/22854662

http://www.clinicaltrials.gov/ct2/show/NCT00477906?term=MVax&rank=1

http://clinicaltrials.gov/show/NCT00660101

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20130309271&OS=20130309271&RS=20130309271

http://www.biotechblog.org/Tags/cancer-treatment-centers-of-america/

http://www.thefreelibrary.com/AVAX+Technologies+Announces+Collaboration+with+Cancer+Treatment...-a0159564876

http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108

http://ih.advfn.com/p.php?pid=nmona&article=61013370

http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html

http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#427   Had to flip them today for over 70% Zilla 07/31/14 01:27:31 PM
#426   Thanks for those .0055's today. :-D Zilla 07/30/14 01:36:32 AM
#425   I have registered a more activity from July rikic 07/18/14 11:00:35 AM
#424   I think we should see something by end BalkanKing 03/25/14 10:41:15 PM
#423   That's old, unfortunately. There was no meeting in FaithfulAndTrue 02/27/14 05:54:27 PM
#422   Correct link: tencoin 02/27/14 10:04:28 AM
#421   Jefferson Scientists' Results Raise Hopes for Ovarian Cancer Vaccine tencoin 02/27/14 09:56:17 AM
#420   Genopietic of France... tis 02/27/14 07:48:04 AM
#419   YES, I do.. >"Does anyone know how old VIPR 02/26/14 07:13:40 AM
#418   Turns out that it was uploaded on January FaithfulAndTrue 02/25/14 10:47:50 AM
#417   Hi FandT, johnny canuck 02/24/14 09:27:09 PM
#416   http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf Does anyone know how ol FaithfulAndTrue 02/24/14 04:56:06 PM
#415   True my brother....My point was only that we NAMweed 02/22/14 09:33:03 PM
#414   yes we have to work as team but ARTIST 02/22/14 08:26:47 PM
#413   Please do not tell people what they should NAMweed 02/21/14 01:22:29 PM
#412   make sure you posting about AVXT ARTIST 02/20/14 06:26:53 PM
#411   the fact that david berd is back is ARTIST 02/20/14 06:24:11 PM
#410   Nothing for nothing. This is a joke bayetta 02/20/14 06:20:58 PM
#409   Actually I am baffled. All the hoopla bayetta 02/20/14 04:21:36 PM
#408   What your posting is not AVXT ovarian studies. bayetta 02/20/14 03:37:08 PM
#407   Three Links... tis 02/20/14 03:33:25 PM
#406   Treatment Eradicated Tumors in 14 of 16 Patients startingboy 02/20/14 03:19:36 PM
#405   what kind of news ovarian? ARTIST 02/20/14 03:12:45 PM
#404   http://online.wsj.com/news/articles/SB10001424052702303636404579393550975534742? startingboy 02/20/14 03:08:14 PM
#403   i have no doubt that something big is startingboy 02/20/14 03:06:13 PM
#402   cnbc cancer big news just now! startingboy 02/20/14 02:41:43 PM
#401   agreex, coolx, wassappx ,peaceax :) startingboy 02/20/14 11:57:06 AM
#400   Cool.....I can post another.....I guess its 3 posts NAMweed 02/20/14 11:42:42 AM
#399   so if you know numbers why you startingboy 02/20/14 11:20:11 AM
#398   I think it depends on the patented protected NAMweed 02/20/14 10:57:42 AM
#397   You do realize that the O/S count as medimpact 02/20/14 10:35:20 AM
#396   my estimated pps is the moon :), but startingboy 02/20/14 08:32:49 AM
#395   Estimated pps on good news and spike interest? NAMweed 02/19/14 04:38:44 PM
#394   Emerging clinical data discussed in this supplement suggest startingboy 02/19/14 11:51:11 AM
#393   we got M-VAX ongoing too http://www.onclive.com/onclive-tv/Dr-Herbst-on-Immunot startingboy 02/19/14 11:47:55 AM
#392   i got a feeling that something big is startingboy 02/19/14 11:44:28 AM
#391   http://web.squ.edu.om/med-Lib/MED_CD/E_CDs/anatomy%20physiology/medialib/news/ar startingboy 02/19/14 11:22:20 AM
#390   "Medical, commercial and patient interest in the new FaithfulAndTrue 02/18/14 05:58:07 PM
#389   1,138,874 volume... tis 02/18/14 04:13:15 PM
#388   we are in the right place at the startingboy 02/17/14 07:51:50 PM
#387   http://medicalxpress.com/news/2014-02-cancer-immune.html startingboy 02/17/14 07:50:49 PM
#386   http://www.onclive.com/publications/obtn/2014/February-2014/Unprecedented-Change startingboy 02/17/14 07:47:26 PM
#385   http://www.washingtonpost.com/national/health-science/new-therapies-raise-hope-f startingboy 02/17/14 07:45:38 PM
#384   http://www.eurekalert.org/pub_releases/2014-02/uotm-cil020714.php startingboy 02/17/14 07:42:16 PM
#383   AstraZeneca raises bet on cancer immunotherapy with Immunocore deal startingboy 02/17/14 07:34:04 PM
#382   Novartis Buys CoStim to Strengthen Immunotherapy Line startingboy 02/17/14 05:45:32 PM
#381   http://hopebyhammett.com/2013/07/29/july-2013-scans-all-clear/ It is so wonderful to be looking to startingboy 02/15/14 12:23:00 AM
#380   this is new to me, another survivor thanks startingboy 02/15/14 12:00:34 AM
#379   it was suspended the last time i check, startingboy 02/14/14 11:32:18 PM
#378   is like avax is saying, we got startingboy 02/14/14 10:51:32 PM
PostSubject